Anavex Life Sciences Corp reports results for the quarter ended December 31 - Earnings Summary

Anavex Life Sciences

12/02/2025 14:31

* Anavex Life Sciences Corp  AVXL.OQ  reported a quarterly
adjusted loss of 14 cents​​ per share for the quarter ended
December 31, lower than the same quarter last year, when the
company reported EPS of -11 cents.  The lone analyst forecast
for the quarter was for a loss of 17 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Anavex Life Sciences Corp's reported EPS for the quarter
was a
loss of 14 cents​.
    * Anavex Life Sciences Corp shares had fallen by 22.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 10.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Anavex Life
Sciences Corp is $41.45 
This summary was machine generated from LSEG data February 12 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.17          -0.14          Beat
 Sep. 30 2024      -0.16          -0.14          Beat
 Jun. 30 2024      -0.16          -0.14          Beat
 Mar. 31 2024      -0.11          -0.13          Missed